Subject
Infectious Diseases,Epidemiology
Reference25 articles.
1. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings;Ford;HIV/AIDS,2011
2. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants;Johnson;Retrovirology,2012
3. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1;Azijn;Antimicrob. Agents Chemother.,2010
4. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000copies/ml or less: week 48 phase III analysis;Molina;AIDS,2013
5. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine–emtricitabine–tenofovir;Patel;HIV/AIDS,2012
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献